- Home
- HOTH vs ADAP Comparison
HOTH vs ADAP Comparison
Compare HOTH & ADAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOTH
- ADAP
- Stock Information
- Founded
- HOTH 2017
- ADAP 2008
- Country
- HOTH United States
- ADAP United Kingdom
- Employees
- HOTH N/A
- ADAP N/A
- Industry
- HOTH Biotechnology: Pharmaceutical Preparations
- ADAP Biotechnology: Pharmaceutical Preparations
- Sector
- HOTH Health Care
- ADAP Health Care
- Exchange
- HOTH Nasdaq
- ADAP Nasdaq
- Market Cap
- HOTH 20.9M
- ADAP 21.3M
- IPO Year
- HOTH 2019
- ADAP 2015
- Fundamental
- Price
- HOTH $1.54
- ADAP $0.16
- Analyst Decision
- HOTH Strong Buy
- ADAP Hold
- Analyst Count
- HOTH 3
- ADAP 6
- Target Price
- HOTH $4.00
- ADAP $1.02
- AVG Volume (30 Days)
- HOTH 1.1M
- ADAP 153.4M
- Earning Date
- HOTH 11-11-2025
- ADAP 11-12-2025
- Dividend Yield
- HOTH N/A
- ADAP N/A
- EPS Growth
- HOTH N/A
- ADAP N/A
- EPS
- HOTH N/A
- ADAP N/A
- Revenue
- HOTH N/A
- ADAP $65,084,999.00
- Revenue This Year
- HOTH N/A
- ADAP N/A
- Revenue Next Year
- HOTH N/A
- ADAP $24.70
- P/E Ratio
- HOTH N/A
- ADAP N/A
- Revenue Growth
- HOTH N/A
- ADAP N/A
- 52 Week Low
- HOTH $0.65
- ADAP $0.04
- 52 Week High
- HOTH $3.80
- ADAP $0.90
- Technical
- Relative Strength Index (RSI)
- HOTH 46.54
- ADAP 53.32
- Support Level
- HOTH $1.46
- ADAP $0.12
- Resistance Level
- HOTH $1.72
- ADAP $0.27
- Average True Range (ATR)
- HOTH 0.13
- ADAP 0.03
- MACD
- HOTH -0.03
- ADAP 0.00
- Stochastic Oscillator
- HOTH 20.00
- ADAP 24.56
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.